Home> Trial Details

Information Clinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth Professionals Patients

RecruitingLast updated:15 August 2023

KRYSTAL-10: This phase III study is evaluating whether a combination of targeted therapies (MRTX849 and Cetuximab) is more effective than chemotherapy (mFOLFOX6 or FOLFIRI regimens) in people with advanced or metastatic colorectal cancer with KRAS G12c mutations who have had previous treatmentA Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy

Clinical summary Eligibilty Participating hospital Support

Clinical summary

Summary

Eligible participants will be randomly allocated into either the Experimental Arm or Active Comparator Arm. In the Experimental Arm, participants will receive MRTX849 in combination with Cetuximab. In the Active Comparator Arm, participants will receive either mFOLFOX6 or FOLFIRI regimens of chemotherapy.

Age

People 18+

Phase

III

Trial Acronym

KRYSTAL-10

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

NCT04793958
849-010 KRYSTAL CT1496

Commercial Sponsor

Mirati Therapeutics Inc.

Scientific Title

A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy

Share with email

Print this page

Download brochure

Eligibility

Inclusion

You have certain types of non-cancer medical conditions.
You have had certain treatments, surgical procedures or drugs.

Exclusion

You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
Your cancer has not spread to other parts of the body.
Your cancer has spread to other parts of the body.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

Information Tell us if you find this trial availability is not accurate.Report inaccuracy